Methylenetetrahydrofolate reductase gene polymorphism in type 1 diabetes mellitus: Relationship to microvascular complications

Egyptian Journal of Medical Human Genetics

Volumn 13, Issue 2, 2012, Pages 139-145

  AboElAsrar, Mohammed A ^a   Hamed, Ahmed Al saeed ^a   Akar, Nejat ^b   Egin, Yonca ^b   Saied, Mai Mohamed Mahmoud ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Methylenetetrahydrofolate reductase gene polymorphism; Microalbuminuria; Microvascular complications; Type 1 diabetes

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; CREATININE; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; SHORT ACTING INSULIN;

ADOLESCENT; ANAMNESIS; ARTICLE; BEDTIME DOSAGE; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENOTYPE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROANGIOPATHY; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PHYSICAL EXAMINATION; SCHOOL CHILD;

EID: 84900378520     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2012.03.010     Document Type: Article

References (18)

1. ISPAD. International society of pediatric and adolescent diabetes. Consensus guideline for the definition/epidemiology and classification of type I DM in children and adolescent. Pediatr Diabetes 2007;7:343-51.
2. Daneman D. Early diabetes related complications in adolescents; risk factors and screening. Hom Res 2005, 63:75-85.
3. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
4. Kim Y. Methylenetetrahydrofolate polymorphism, folate, and cancer risk: a paradigm of gene nutrient interactions in carcinogenesis. Nat Rev 2000, 58:205-217.
5. Wiltshire EJ, Mohsin F, Chan A, Donaglue KC. Methylenetetrahydrofolate reductase and methionine synthase reductase gene polymorphisms and protection from microvascular complications in adolescents with type 1 diabetes. Pediatr Diabetes 2008;9(Part II):348-53.
6. Dimitra D., King J.C. Median/ulnar promoter potential identification and localization. Muscle Nerve 1995, 18(5):518-525.
7. Stetson D.S., Albers J.W., Silverstein B.A., Wolfe R.A. Effect of age, sex and arthropometric lacturs on nerve conduction measures. Muscle Nerve 1992, 15(10):1095-1104.
8. Frosst P., Blom H.J., Milos R., Goyette P., et al. A canadiate genetic risk factor for vascular disease: a common mutation in methylentetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
9. Kang S.S., Wong P.W., Bock H.G., Horwitz A., Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 1991, 48:546-551.
10. Sun J., Xu Y., Zhu Y., Lu H. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 2004, 67:185-190.
11. Zintzraras E., Uhlig K., Koukoulis G.N., et al. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis. J Hum Genet 2007, 52:881-890.
12. Fryer R.H., Wilson B.D., Gubler D.B., Fitzgerald L.A., Rodgers G.M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993, 13(9):1327-1333.
13. Hofmann M.A., Kohl B., Zumbach M.S., Borcea V., et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998, 21(5):841-848.
14. Ragone R. Homocystine solubility and vascular disease. FASEB J 2002, 16(3):401-404.
15. Dinleyici E.C., Kirel B., Alatas O., Muslumanoglu H., Kilic Z., Dogruel N. Plasma total homocysteine levels in children with type 1 diabetes: relationship with vitamin status, methylene tetrahydrofolate reductase genotype, disease parameters and coronary risk factors. J Trop Pediatr 2006, 52(4):260-266.
16. Ukinc K., Ersoz H.O., Karahan C., Erem C., et al. Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine 2009, 36(2):255-261.
17. Zintzraras E., Chatzoulis D.Z., Karabatsas C.H., Stefanidis I. The relationship between C 677T Methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet 2005, 50(6):267-275.
18. Maeda M., Fujio Y., Azuma J. MTHFR gene polymorphism and diabetic retinopathy. Curr Diabetes Rev 2006, 2(4):467-476.